WO2021194186A1 - Vgll1 펩타이드를 포함하는 암 치료용 조성물 - Google Patents
Vgll1 펩타이드를 포함하는 암 치료용 조성물 Download PDFInfo
- Publication number
- WO2021194186A1 WO2021194186A1 PCT/KR2021/003496 KR2021003496W WO2021194186A1 WO 2021194186 A1 WO2021194186 A1 WO 2021194186A1 KR 2021003496 W KR2021003496 W KR 2021003496W WO 2021194186 A1 WO2021194186 A1 WO 2021194186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vgll1
- cancer
- peptide fragment
- variant
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 84
- 201000011510 cancer Diseases 0.000 title claims abstract description 76
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 77
- 239000000203 mixture Substances 0.000 title claims description 16
- 101000622237 Homo sapiens Transcription cofactor vestigial-like protein 1 Proteins 0.000 claims abstract description 162
- 102100023478 Transcription cofactor vestigial-like protein 1 Human genes 0.000 claims abstract description 162
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 90
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 90
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims description 51
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 41
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 32
- 206010017758 gastric cancer Diseases 0.000 claims description 32
- 201000011549 stomach cancer Diseases 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 14
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 11
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 32
- 230000035755 proliferation Effects 0.000 abstract description 16
- 230000009545 invasion Effects 0.000 abstract description 7
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 105
- 235000001014 amino acid Nutrition 0.000 description 52
- 229940024606 amino acid Drugs 0.000 description 50
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 45
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 40
- 235000004400 serine Nutrition 0.000 description 40
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 34
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 34
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 34
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 230000035772 mutation Effects 0.000 description 19
- 101000597045 Homo sapiens Transcriptional enhancer factor TEF-3 Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 description 16
- 230000026731 phosphorylation Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 230000009702 cancer cell proliferation Effects 0.000 description 14
- 238000012790 confirmation Methods 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102220473708 Ras-related protein Rab-5A_S84A_mutation Human genes 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000012097 Lipofectamine 2000 Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 102220352372 c.148T>G Human genes 0.000 description 5
- 230000004709 cell invasion Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 102220131212 rs886046111 Human genes 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010088535 Pep-1 peptide Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108700038175 YAP-Signaling Proteins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102220323085 rs1554893756 Human genes 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006126 farnesylation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000622236 Homo sapiens Transcription cofactor vestigial-like protein 3 Proteins 0.000 description 1
- 101000805518 Homo sapiens Transcription cofactor vestigial-like protein 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101150035730 Mmp9 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700040013 TEA Domain Transcription Factors Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100023476 Transcription cofactor vestigial-like protein 3 Human genes 0.000 description 1
- 102100038034 Transcription cofactor vestigial-like protein 4 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000016515 regulation of signal transduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220005293 rs35960772 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003355 serines Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a composition for treating cancer comprising a VGLL1 peptide and a method for treating cancer using the same.
- the present invention was made with the support of the Korean government in accordance with the Ministry of Science and ICT's task number 1711098598, "Basic Research Project in Science and Engineering".
- the present invention was made with the support of the Korean government in accordance with the Ministry of Science and ICT's task number 1711081422, "Original technology development project (biomedical technology)”.
- the present invention was made with the support of the Korean government in accordance with the Ministry of Science and ICT's task number 1711100103, "Main Project (2019-2023)".
- Cancer has a high mortality rate worldwide and is the second most common cause of death in Western societies after cardiovascular disease.
- colorectal cancer, breast cancer, prostate cancer, etc. continue to increase due to the aging of the population, generalization of high-fat diet intake due to westernization of diet, rapid increase in environmental pollutants, and increase in alcohol consumption.
- anticancer substances that can contribute to the promotion of human health, the improvement of the quality of healthy life, and the promotion of human health by enabling the early prevention and treatment of cancer.
- a substance that causes mutation is called a carcinogen, and the step in which genetic modification occurs by this carcinogen is called initiation.
- cancer suppressor genes eg, p53, PTEN, INK family, RB
- constitutive active mutations active mutants, such as EGFR mt , RasG 12V
- active mutants such as EGFR mt , RasG 12V
- epidermal growth factor produces an activation signal by binding to the EGF receptor, but active mutants always send an activation signal to the downstream signaling system even if the ligand does not bind to the receptor.
- One mutant cell generated in this process must penetrate the immune defense system in the body and grow into a tumor mass. This process is called promotion.
- the promotion process requires a long time and mainly consists of activation of the signal transduction system.
- TGF- ⁇ Transforming growth factor- ⁇
- EMT epithelial-mesenchymal transition
- the vestigial (vg) gene which is a coactivator of the Drosophila transcription factor, and the vestigial-like (VGLL) gene, which has structural similarity, acts as a cofactor for the transcription factors TEADs (TEA domain transcription factors) that bind to the TEA region.
- TEADs TEA domain transcription factors
- VGLL3 overexpression in gastric cancer patients is known to be associated with a low survival rate.
- VGLL4 which binds TEAD competitively with YAP (Yes-associated protein), has been reported as a tumor suppressor.
- VGLL1 forms a VGLL1-TEAD complex with high structural homology with YAP and TAZ (transcription coactivator with a PDZ-binding motif).
- TAZ transcription coactivator with a PDZ-binding motif.
- VGLL1 which is highly expressed in gastric cancer and correlates with the prognosis of patients with PIK3CA or PIK3CB overexpression, as a gene associated with gastric cancer malignancy.
- the transcription of VGLL1 is regulated through the signaling mechanism of PI3K-AKT- ⁇ -catenin.
- the VGLL1-TEAD complex was involved in the proliferation and metastasis of gastric cancer by increasing the expression of Matrix metallopeptidase 9 (MMP9).
- MMP9 Matrix metallopeptidase 9
- VGLL1 The specific action of VGLL1 in relation to the proliferation and metastasis of a series of cancer cells is unknown. With respect to VGLL1, there have been reports of a method for predicting the survival period of a patient with lung cancer using VGLL1 as a biomarker, or cancer cell proliferation or cancer metastasis related to the enhancement of VGLL1 expression in some literatures.
- the present inventors have found that the peptide fragment of VGLL1 not only inhibits the expression of MMP9 but also inhibits the proliferation of cancer cells, thereby completing the present invention as a cancer therapeutic agent.
- An object of the present invention is to provide a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less.
- Another object of the present invention is to provide a method for treating cancer comprising administering the VGLL1 peptide fragment or a variant thereof to a subject.
- One aspect of the present invention provides a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less.
- the VGLL1 peptide fragment or variant thereof may be a VGLL1 peptide fragment or variant thereof having a sequence of 6 to 25 amino acids.
- the VGLL1 peptide fragment or variant thereof may be a VGLL1 peptide fragment or a variant thereof comprising the serine sequence at position 84 in the amino acid sequence between positions 52 and 115 of SEQ ID NO: 1.
- the VGLL1 peptide fragment or a variant thereof may be a VGLL1 peptide fragment or a variant thereof consisting of the 84th serine and 6 to 20 amino acids adjacent thereto.
- the VGLL1 peptide fragment or variant thereof may be any one selected from the group consisting of SEQ ID NOs: 2 to 9, the VGLL1 peptide fragment or variant thereof.
- it may be a VGLL1 peptide fragment or a variant thereof further comprising a cell-penetrating peptide.
- the cell-penetrating peptide may be any one selected from the group consisting of SEQ ID NOs: 12 to 19, a VGLL1 peptide fragment or a variant thereof.
- it may be a pharmaceutical composition for preventing or treating cancer comprising the VGLL1 peptide fragment or a variant thereof.
- the cancer is gastric cancer, liver cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, head and neck squamous cell carcinoma, esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, mesothelioma, melanoma, sarcoma, It may be a pharmaceutical composition for the prevention or treatment of any one cancer selected from the group consisting of osteosarcoma, liposarcoma, thyroid cancer, eugenoma, and hematologic cancer.
- the cancer may be a pharmaceutical composition for the prevention or treatment of gastric cancer.
- Another aspect of the present invention provides a method of treating cancer comprising administering the composition to a subject.
- the peptide fragment of VGLL1 containing the 84th serine of the present invention has an excellent effect in preventing and treating cancer by inhibiting the proliferation of cancer cells and inhibiting the invasion of cancer cells.
- FIG. 11 shows the results of confirming the inhibition of proliferation of cancer cells by treatment with a peptide fragment of VGLL1 and a mutant thereof.
- the present invention provides a VGLL1 peptide fragment or variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less.
- the variant of the VGLL1 peptide fragment containing the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less includes the 84th serine of SEQ ID NO: 1 while containing the 84th serine (Serine) It may be any sequence having up to 35 between positions 115 and 115 or a variant thereof.
- peptide and “protein” are used interchangeably and include reference to a polymer of amino acid residues.
- the terms apply to natural amino acid polymers as well as amino acid polymers in which one or more amino acid residues are artificial chemical analogues of the corresponding natural amino acid.
- the terms also apply to those polymers containing conservative amino acid substitutions such that the protein remains functional.
- the peptide may be synthesized using a gene recombination and protein expression system, and preferably synthesized in vitro through a peptide synthesizer or the like.
- VGLL1 peptide refers to a polypeptide corresponding to the full-length VGLL1 protein. The term also includes any homologue, analog, fragment or derivative of the VGLL1 protein. In one embodiment, the isolated VGLL1 peptide has the amino acid sequence (SEQ ID NO: 1).
- VGLL1 encoding nucleic acid means DNA or RNA encoding at least a portion of a VGLL1 polypeptide or variant thereof.
- the VGLL1 peptide fragment having a length of 35 amino acids or less may be 7 to 35 amino acids, preferably 7 to 25 amino acid residues, and more preferably 6 to 15 amino acids. or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 , 30, 31, 32, 33, 34, or 35 amino acids in length, or an amino acid chain comprising any conceivable range thereof.
- the VGLL1 peptide fragment of the present disclosure in some embodiments, has no more than 35 contiguous amino acids in the amino acid sequence between positions 52 and 115 of the VGLL1 peptide sequence of SEQ ID NO: 1 and includes Serine at position 84 may consist of a sequence of
- the VGLL1 peptide fragment according to the present invention may be a 30 amino acid sequence having the amino acid sequences 55 to 84 of SEQ ID NO: 1 when the 84th serine of the sequence is included at the end.
- the VGLL1 peptide fragment may be a 35 amino acid sequence having the amino acid sequence 80 to 114 of SEQ ID NO: 1 including the 80th serine of the sequence at the end.
- amino acids having a sequence of 35 or less amino acids adjacent to and centering on the 84th serine sequence are fragments of the VGLL1 peptide included in the scope of the present invention.
- it may be any sequence such that the total number of amino acid sequences is 35 or less, centering on the 84th serine sequence of SEQ ID NO: 1.
- it may be a sequence comprising or consisting of serine at position 84 of the amino acid sequence of the VGLL1 protein and 8 to 25, preferably 7 to 20 amino acids, and more preferably 6 to 15 amino acids adjacent thereto.
- any sequence according to the present invention is, for example, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 of the VGLL1 peptide sequence of SEQ ID NO: 1 84, 85, 86 starting from any selected amino acid sequence at position , 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, or 82 , 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 , 112, 113, 114 or any selected amino acid sequence up to the 115th amino acid sequence, and any sequence that satisfies the above-mentioned 35 or less can be included in the peptide fragment within the
- amino acid sequence of SEQ ID NO: 2 consisting of sequences 77 to 91 of VGLL1. More specifically, it may be the amino acid sequence of SEQ ID NO: 9 consisting of sequences 82 to 88 of VGLL1.
- Such exemplary VGLL1 peptide fragment sequences are shown in SEQ ID NOs: 2 to 9 of Table 1 below, and this sequence includes the 84th serine sequence of the VGLL1 peptide, and corresponds to the sequence shown as an example, It is not limited.
- SEQ ID NO:2 SEQ ID NOs: 77-91 PNQWRYSSPWTKPQP SEQ ID NO:3 SEQ ID NOs: 78-90 NQWRYSSPWTKPQ SEQ ID NO:4 SEQ ID NOs: 79-89 QWRYSSPWTKP SEQ ID NO:5 SEQ ID NOs: 80-88 WRYSSPWTK SEQ ID NO:6 SEQ ID NOs: 80-87 WRYSSPWT SEQ ID NO:7 SEQ ID NOs: 80-86 WRYSSPW SEQ ID NO:8 SEQ ID NOs: 81-87 RYSSPWT SEQ ID NO: 9 SEQ ID NOs: 82-88 YSSPWTK
- biologically active refers to a peptide fragment having a similar structural function, and/or a regulatory function, and/or a biochemical function similar to that of an individual wild-type polypeptide as well as a peptide according to the present invention.
- variant refers to any having a substitution, deletion or addition (or any combination thereof) from one (or more) amino acids or to a sequence, including allelic mutations, compared to a wild-type peptide. refers to a peptide (including a peptide encoded by a corresponding nucleic acid). In certain embodiments, the resulting polypeptide retains at least 75%, 80%, 85%, 90%, 95%, 99% or more of biological activity as compared to a wild-type polypeptide when used in the present invention. .
- the variant according to the present invention is a sequence necessarily containing S84 of SEQ ID NO: 1, and is a sequence having 35 or less amino acids in which a mutation occurs at any site of the VGLL1 peptide between positions 52 and 115. maintaining activity.
- Sequence identity or homology can be determined using standard techniques known in the art. Alignment will include the introduction of gaps in the sequence being aligned. It is also understood that for sequences comprising more or fewer amino acids compared to the proteins disclosed herein, the percentage of homology will be determined based on the number of homologous amino acids compared to the total number of amino acids.
- variants of the VGLL1 polypeptide have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least the peptide sequence of SEQ ID NO: 1 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence homology.
- the variant according to the present invention is a variant of the VGLL1 peptide fragment containing the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less, and the 52nd to 115th of SEQ ID NO: 1 at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least taking into account the corresponding sequence between the 52nd to 115th sequences above. 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence homology.
- a “deletion” is defined as a change in a nucleotide or amino acid sequence that lacks one or more nucleotide or amino acid residues, respectively, compared to a wild-type polynucleotide or polypeptide.
- insertion or “addition” is a change in nucleotide or amino acid sequence resulting from the addition of one or more nucleotide or amino acid residues, respectively, compared to a wild-type polynucleotide or polypeptide.
- substitution results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively, compared to a wild-type polynucleotide or polypeptide.
- the cytokine TGF-b induces phosphorylation of intracellular signaling proteins.
- Treatment of TGF-b in cancer cells can induce phosphorylation of VGLL1.
- a peptide fragment including S84 of VGLL1 can inhibit the expression of MMP9 by competitively inhibiting the binding of VGLL1 and TEAD4.
- Amino acids that can be phosphorylated by TGF-b include serine, threonine and tyrosine. Accordingly, although not limited thereto, it may be preferable that the sequences 54, 59, 61, 62, 64, 66, 74, 76, 82, 83, 84 and 96 in the amino acid sequence of SEQ ID NO: 1 are maintained without mutation. have.
- preferred amino acid mutation at the substitution position may be performed based on the similarity of residues in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or amphiphilic properties.
- negatively charged amino acids include aspartic acid and glutamic acid
- positively charged amino acids include lysine and arginine
- amino acids having an uncharged polar head group having a similar hydrophilicity value include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine, threonine, phenylalanine and tyrosine;
- Such mutations may include conservative substitutions.
- a 'conservative substitution' refers to a substitution in which an amino acid is substituted with another amino acid having similar properties so that those skilled in the art can predict that the secondary structure and hydropathic nature (hydropathic nature) of the polypeptide are substantially unchanged.
- the following groups of amino acids exhibit conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
- Exemplary amino acid substitutions that do not show a change in biological activity may include, but are not limited to, mutations at positions 85 and 87 of SEQ ID NO: 1.
- P85A, T85A in SEQ ID NO: 1 may be a mutation.
- the present invention includes, but is not limited to, the following amino acid mutations at the aforementioned substitution positions: S-A, P->A, T->A, or Y->A.
- variants may include non-conservative alterations.
- the variant polypeptide may differ from the native sequence by substitution, deletion or addition of 5 amino acids or fewer amino acids.
- variantants may also be altered, for example, by deletion or addition of amino acids with minimal impact on the secondary structure and hydropathic properties of the polypeptide.
- the variant is phosphorylation (phosphorylation), sulfation (sulfation), acrylation (acrylation), glycosylation (glycosylation), methylation (methylation), farnesylation (farnesylation), acetylation (acetylation) and amylation (amidation) It may be modified (modification), etc.
- the VGLL1 peptide fragment or variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less may further include a cell-penetrating peptide sequence for intracellular penetration.
- the cell-penetrating peptide is a kind of signal peptide and is a peptide sequence that aims to transfer substances into cells. It mainly consists of a peptide sequence of about 7-30 amino acids, and any sequence having a signal peptide that can be delivered into a cell may be included in the present invention.
- the cell-penetrating peptide mainly contains basic amino acid residues such as lysine/arginine, and thus serves to penetrate the fused proteins into the cell membrane and into the cell.
- the cell-penetrating peptide is HIV-1 Tat protein, Drosophila antennapedia homeodomain (phenetratin), HSV VP22 transcriptional regulatory protein, vFGF-derived MTS peptide, PTD-5, transpotan or Pep-1 peptide Sequences derived from, but are not limited thereto.
- viruses or cationic peptides are biologically active substances.
- HIV-1 Tat SEQ ID NO: 12
- YGRKKRRQRRR Penetratin SEQ ID NO: 13
- RQIKIWFQNRRMKWKK HSV VP22 SEQ ID NO: 14
- DAATATRGRSAASRPTERPRAPARSASRPRRPVE MTS SEQ ID NO: 15
- AAVALLPAVLLAAP Transportan SEQ ID NO: 16
- GWTLNSAGYLLGKINLKALAALAKKIL PEP-1 SEQ ID NO: 17
- KETWWETWWTEWSQPKKKRKV Poly arginine
- RRRRRRR PTD-5 SEQ ID NO: 19
- sequence of SEQ ID NO: 12 may be linked to a VGLL1 peptide fragment or a variant thereof.
- a sequence may be, for example, a sequence peptide fragment such as SEQ ID NO: 27, SEQ ID NO: 29.
- SEQ ID NO: 30 or SEQ ID NO: 31 a variant of the peptide fragment and a cell-penetrating sequence may be linked.
- the cell-penetrating peptide can provide a fusion peptide comprising a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less.
- the present invention also provides a nucleic acid sequence encoding the VGLL1 peptide fragment or variant thereof, and a fusion peptide in which a cell-penetrating peptide is linked thereto.
- Nucleic acid is intended to include DNA and RNA, and may be double-stranded or single-stranded.
- a nucleic acid encoding a peptide can be operably linked to a peptide produced in an appropriate expression system using expression vectors and methods well known in the art of molecular biology. Nucleic acids encoding the peptides disclosed herein can be incorporated into any expression vector that ensures proper expression of the peptides. Possible expression vectors include, but are not limited to, plasmids, or modified viruses (eg replication deficient retroviruses, adenoviruses and adeno-associated viruses) so long as the vector is suitable for transformation of the host cell.
- a recombinant expression vector “suitable for transformation of a host cell” is a nucleic acid molecule of the present disclosure, operably linked to a nucleic acid molecule, and comprising regulatory sequences selected based on the host cell used for expression.
- operably linked or “operably linked” are used interchangeably and are intended to mean that the nucleic acid is linked to regulatory sequences in a manner that enables expression of the nucleic acid.
- the present disclosure provides a recombinant expression vector comprising a nucleic acid encoding a peptide and regulatory sequences necessary for transcription and translation of the inserted protein-sequence.
- Suitable regulatory sequences can be derived from a variety of sources, including bacterial, fungal or viral genes. The selection of appropriate regulatory sequences is generally dependent on the host cell selected and can be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include transcriptional promoters and enhancers or RNA polymerase binding sequences, ribosome binding sequences, including translation initiation signals.
- sequences may be incorporated into the expression vector, such as origins of replication, additional DNA restriction sites, enhancers, and sequences that confer transcriptional inducibility. It will also be understood that the necessary regulatory sequences may be supplied by the native protein and/or flanking regions thereof.
- Recombinant expression vectors can be introduced into host cells to produce transformed host cells.
- the term “transformed host cell” is intended to include prokaryotic and eukaryotic cells transformed or transfected with the recombinant expression vectors of the present disclosure.
- the terms “transformed with”, “transfected with”, “transformation” and “transfection” refer to the transfer of a nucleic acid (eg, a vector) into a cell by one of many possible techniques known in the art. It is intended to include introduction.
- Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells.
- the proteins of the present disclosure can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus), yeast cells, or mammalian cells.
- Nucleic acid molecules of the present disclosure can also be synthesized chemically, using standard techniques. A variety of methods are known for chemically synthesizing polydeoxy-nucleotides, including fully automated solid-phase synthesis in commercially available DNA synthesizers, such as peptide synthesis.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less.
- the present invention also provides a pharmaceutical composition for preventing or treating cancer comprising a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less to provide.
- the present invention also provides a pharmaceutical composition for inhibiting metastasis of cancer comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and comprising a VGLL1 peptide fragment having a length of 35 amino acids or less or a variant thereof to provide.
- composition according to the present invention has excellent effects in the prevention, metastasis, and treatment of cancer because the peptide of VGLL1 inhibits cancer cell proliferation and inhibits cancer cell invasion.
- the composition according to the present invention includes both the direct therapeutic effect and the metastasis inhibitory effect as well as the action as an anticancer adjuvant.
- treatment and “treating” refer to the administration or application of a therapeutic agent to a subject or the performance of a procedure or modality in a subject for the purpose of obtaining the benefit of treatment of a disease or health-related condition.
- Prevention refer to an approach for preventing, inhibiting or reducing the likelihood of occurrence or recurrence of a disease or condition. Also delaying the onset or recurrence of a disease or condition, or the occurrence or recurrence of a disease or condition. It refers to delaying relapse.
- subject and patient refer to a human or non-human, such as a primate, mammal, or vertebrate. In certain embodiments, the subject is a human.
- therapeutic benefit refers to anything that promotes or enhances the health of a subject in connection with the medical treatment of such condition. This includes, but is not limited to, a decrease in the frequency or severity of signs or symptoms of a disease.
- treating cancer may include reducing the size of the tumor, reducing the invasiveness of the tumor, reducing the rate of growth of the cancer, or preventing metastasis. Treating cancer may also refer to prolonging the survival of a subject having cancer.
- cancer is gastric cancer, liver cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, head and neck squamous cell carcinoma, esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, mesothelioma, melanoma, sarcoma, osteosarcoma, liposarcoma, thyroid cancer , pancreatic cancer, and blood cancer.
- an anticancer agent for example, promotes the death of cancer cells, induces apoptosis in cancer cells, reduces the growth rate of cancer cells, reduces the prevalence or number of metastases, reduces tumor size, or By inhibiting tumor growth, reducing blood supply to a tumor or cancer cells, promoting an immune response against cancer cells or tumors, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer; by negatively affecting the cancer cells/tumors of a subject.
- the phrase "pharmaceutically or pharmacologically acceptable” refers to molecular substances and compositions that, when appropriate, do not cause side effects, allergic reactions or other inappropriate reactions when administered to animals, such as humans.
- pharmaceutical compositions comprising antibodies or additional active components.
- animal eg, human
- manufacturing must meet sterility, pyrogenicity, general safety and purity standards as required by the FDA Office of Biological Standards.
- the peptide fragment or variant thereof according to the present invention further includes a cell-penetrating peptide, so that it can be more easily delivered to cells in the human body.
- compositions for use in the present invention may be formulated by standard techniques using one or more physiologically acceptable carriers or excipients. Suitable pharmaceutical carriers are disclosed herein and in Remington: The Science and Practice of Pharmacy, 21st Ed., University of the Sciences in Philadelphia, Lippencott Williams & Wilkins (2005).
- the peptides of the invention may be formulated for administration by any suitable route, for example via inhalation, topically, nasally, orally, parenterally or rectally. Accordingly, administration of the above-mentioned pharmaceutical compositions can be performed intradermally, subcutaneously, intravenously, intramuscularly, intranasally, by inhalation, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary, subcutaneous or This can be done by intratumoral injection, using a syringe or other device. Transdermal administration is also contemplated as inhalation or aerosol administration. Tablets and capsules may be administered orally, rectally or intravaginally.
- the pharmaceutical composition will typically comprise a peptide, or peptide, dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier.
- a pharmaceutically acceptable carrier preferably an aqueous carrier.
- the peptides may be provided together or separately.
- a variety of aqueous carriers can be used, such as buffered saline and the like. These solutions are sterile and generally free of undesirable substances.
- These compositions may be sterilized by conventional, well-known sterilization techniques.
- the composition may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents and the like, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium It may contain lactate etc.
- the concentration of peptides in these formulations can vary widely and will be selected based primarily on fluid volume, viscosity, body weight, etc., depending on the particular mode of administration selected and the needs of the patient.
- the pharmaceutical composition of the present invention is suitable for parenteral administration, including intravenous administration or body cavity administration.
- the peptides of the invention may be formulated for parenteral administration by injection, for example by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, for example, in ampoules or multi-dose containers, with an added preservative.
- Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are preferably prepared from fatty emulsions or suspensions.
- the composition may be sterilized and/or the composition may contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, dissolution promoters, salts for regulating the osmotic pressure and/or buffers.
- the active ingredient may be in powder form, which is formulated by means of a suitable vehicle, for example sterile, pyrogen-free water, before use.
- a suitable vehicle for example sterile, pyrogen-free water
- the active ingredient may also contain other therapeutically valuable substances.
- the compositions are prepared according to the respective conventional mixing, granulating or coating methods, and they contain from about 0.1 to 75%, preferably from about 1 to 50% of the active ingredient.
- the pharmaceutical composition or medicament may take the form of, for example, tablets or capsules prepared by conventional means, together with pharmaceutically acceptable excipients.
- the active ingredient i.e., the composition of the present invention, is added to (a) a diluent or filler such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose (such as ethyl cellulose, microcrystalline cellulose), glycine, pectin, polyacrylic rate and/or calcium hydrogen phosphate, calcium sulfate, (b) lubricants such as silica, talcum, stearic acid, its magnesium or calcium salt, metallic stearate, colloidal silicon dioxide, hydrogenated vegetable oil, corn starch, sodium with benzoate, sodium acetate and/or polyethylene glycol; for tablets also (c) binders, for example magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyviny
- the present invention administers the pharmaceutical composition to a patient in a therapeutically effective dose for preventing, treating or inhibiting a disease such as cancer or a malignant state thereof.
- the pharmaceutical composition is administered to the patient in an amount sufficient to elicit an effective therapeutic or diagnostic response in the patient.
- An effective therapeutic or diagnostic response is one that at least partially arrests or slows the symptoms or complications of the disease or malignancy.
- An amount suitable to accomplish this is defined as a “therapeutically effective amount”.
- the dosage of the peptide to be administered depends on the mammalian species, body weight, age, individual conditions, the surface area of the region to be treated, and the dosage form.
- the size of the dose will also be determined by the presence, nature and extent of any side effects that accompany administration of a particular compound in a particular patient.
- a unit dosage for administration to a mammal of about 50 to 80 kg, preferably a human, may contain an amount of about 1 mg/kg to 5 mg/kg of peptide.
- the dosage of a compound of the present invention is a dosage sufficient to achieve the desired effect.
- An optimal dosing schedule can be calculated from the measurement of the peptide, its accumulation in the patient's body. It may be given more than once a day, a week, a month, or a year. Those skilled in the art can readily determine the optimal dosage, method of administration, and repetition rate. One of ordinary skill in the art will be able to determine the optimal administration for administration of a peptide to a human according to established protocols known in the art and disclosed herein.
- the actual dosage of the active ingredient should be determined in light of several related factors such as the disease to be treated, the severity of the disease, the route of administration, the patient's weight, age, and sex, and therefore, the dosage may be any It is not intended to limit the scope of the present invention in any way.
- the present invention also provides a VGLL1 peptide fragment or a variant thereof comprising the 84th serine of the VGLL1 peptide sequence of SEQ ID NO: 1 and having a length of 35 amino acids or less for use in the prevention or treatment of cancer.
- the present invention also provides a VGLL1 peptide fragment comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less in the manufacture of a medicament for use in the prevention or treatment of cancer, or its Uses of the variant are provided.
- the present invention also comprises administering to a subject a therapeutically effective amount of a VGLL1 peptide fragment or variant thereof comprising the 84th serine of the peptide sequence of VGLL1 of SEQ ID NO: 1 and having a length of 35 amino acids or less It provides a method of treating cancer, comprising.
- the peptide fragment of VGLL1 or a mutant thereof has an excellent effect in preventing and treating cancer by inhibiting cancer cell proliferation and cancer cell invasion, thereby completing the present invention.
- this will be looked into in detail.
- the human gastric cancer cell line NUGC3 was treated with TGF- ⁇ at each time period, mRNA was extracted from the cells, and complementary DNA was synthesized, followed by Matrix metalloproteinase 9 RT-PCR was performed using (MMP9) primers (Table 4).
- Example 1-2 Confirmation of cancer cell proliferation and invasion by MMP9
- the gastric cancer cell line NUGC3 was cultured overnight in a 6-well plate, and then 20 nM siSC and siMMP9 (SEQ ID NO: 22) were mixed with Lipofectamine 2000 and treated with the cell line. After 48 hours, mRNA was extracted from the cells and complementary DNA was synthesized, followed by RT-PCR using the MMP9 primer (FIG. 2A).
- the gastric cancer cell line NUGC3 was cultured in a 96-well plate the next day, and 20 nM siSC and siMMP9 were mixed with Lipofectamine 2000 and treated with the cell line. After 48 hours, cells were fixed using 1% formalin solution. Thereafter, the cells were stained with 0.4% Sulforhodamine B solution for 1 hour, washed with acetic acid and dried. Then, the cells were dissolved in a 10 mM Tris solution and absorbance was measured at 540 nm using an ELISA plate reader ( FIG. 2B ).
- a cell culture insert was fixed in a 24-well plate, and 100 ⁇ l of Matrigel was diluted 20-fold and added. The reaction was carried out at 37°C for 1 hour or more. 700 ⁇ l of medium containing 10% serum was added to a 24-well plate under the insert. MMP knockdown (knockdown) cells with the above siRNA were added to the insult according to 300 ⁇ l of serum-free medium to a concentration of 5 x 10 5 . After incubation for 48 hours, the insult was removed and fixed in 10% formalin solution. Cells remaining inside the insert were removed with a cotton swab and washed with water.
- FIG. 2A shows the result of reduced expression of MMP9 according to siRNA (siMMP9) treatment.
- FIG. 2B shows the result that the cell viability is greatly reduced by reducing the expression of MMP9 according to the siRNA (siMMP9) treatment.
- FIG. 2C shows the result of greatly reduced cell invasiveness according to siRNA (siMMP9) treatment.
- MMP9 promoter luciferase activity was confirmed after TGF- ⁇ treatment.
- the gastric cancer cell line NUGC3 was cultured in a 48-well plate at a concentration of 2 x 10 4 cells/well. The next day, the pGL4.17-luciferase vector into which the MMP9 gene was inserted was transfected into cells using Lipofectamine 2000.
- siSC SEQ ID NO: 23: 5′-CCUACGCCACCAAUUUCGUdTdT-3′
- siVGLL1 SEQ ID NO: 24: 5′-AGCCUAUAAAGACGGAAUGGAAUdTdT-3′
- siTEAD4 SEQ ID NO: 25: 5′-GACACUACUCUUACCGCAU
- siYAP SEQ ID NO: 26: 5'-CCACCA AGCUAGAUAAAGAAAdTdT-3'
- Example 2-2 Confirmation of the effects of VGLL1 and TEAD4 on MMP9 mRNA expression by TGF- ⁇
- MMP9 mRNA expression was confirmed by RT-PCR after TGF- ⁇ treatment.
- the gastric cancer cell line NUGC3 was cultured in a 6-well plate the next day, and 20 nM siSC, siVGLL1, siTEAD4, and siYAP were mixed with Lipofectamine 2000 to treat the cell line. The next day, after treatment with TGF- ⁇ for 18 hours, mRNA was extracted from the cells and complementary DNA was synthesized, followed by RT-PCR.
- VGLL1 is phosphorylated by TGF- ⁇
- serine at positions 50, 84, and 124 of the VGLL1 amino acid sequence was mutated to alanine, and then, the phosphorylation of VGLL1 was checked.
- serines at positions 50, 84, and 124 were replaced with alanine using site-direct mutagenesis products in pcDNA3-HA-VGLL1- vector.
- pcDNA3-HA(EV), pcDNA3-HA-VGLL1(WT), pcDNA3-HA-VGLL1-S50A (S50A mutation), pcDNA3-HA- VGLL1-S84A (S84A mutant) and pcDNA3-HA-VGLL1-S124A (S124A mutant) were mixed with Turbofect to transform the cell line.
- TGF- ⁇ was treated for 15 minutes, and proteins were extracted from the cells using RIPA buffer. The extracted protein was subjected to immunoprecipitation using agarose bound with HA antibody and separated by electrophoresis. Confirmed.
- the GFP-TEAD4 vector and pcDNA3-HA (EV), pcDNA3-HA-VGLL1 (WT), pcDNA3-HA-VGLL1-S50A (S50A mutation), pcDNA3-HA-VGLL1-S84A (S84A mutation), pcDNA3- HA-VGLL1-S124A (S124A mutation) was mixed with Turbofect and transformed into a cell line cultured for 24 hours. After 48 hours, proteins were extracted from the cells using a lipid buffer, immunoprecipitated using agarose to which HA antibodies were bound, and separated by electrophoresis. was used to confirm the protein expression of genes.
- MMP9 protein expression was confirmed by Western blot using the VGLL1 vectors used in ⁇ Example 3>.
- pcDNA3-HA (EV), pcDNA3-HA-VGLL1 (WT), pcDNA3-HA-VGLL1-S50A (S50A), pcDNA3-HA -VGLL1-S84A (S84A) and pcDNA3-HA-VGLL1-S124A (S124A) were mixed with Turbofect to transform the cell line.
- TGF- ⁇ was treated for 18 hours, and proteins were extracted from the cells using a lipa buffer. After the extracted protein was separated by electrophoresis, the protein expression was confirmed by using the MMP9, HA, and GAPDH antibodies in the moved polyvinylidene fluoride membrane.
- FIG. 7 The results are shown in FIG. 7 . As can be seen in FIG. 7 , it was confirmed that the expression of MMP9 protein by TGF- ⁇ was decreased in the cell line in which the serine 84 of VGLL1 was substituted with alanine. This indicates that phosphorylation of VGLL1 by TGF- ⁇ is important for MMP9 expression, and that serine at position 84 of the VGLL1 peptide is an important factor.
- Example 6-1 S84 VGLL1 peptide fragment reduces MMP9 expression by TGF- ⁇
- a peptide fragment having the sequence shown in Table 6 below was prepared to check whether the expression of MMP9 could be inhibited, and its MMP9 expression inhibitory effect was confirmed.
- the peptide fragment sequence in Table 6 provides sequences 77 to 91 of VGLL1 including S84 of VGLL1.
- the sequence of SEQ ID NO: 27 includes the fluorescein moiety (FITC) and YGRKKRRQRRR, which is an HIV TAT transduction domain sequence required for introduction into cells, and sequences 77 to 91 of VGLL1 are linked thereto.
- SEQ ID NO: 28 shows a sequence in which S84 of VGLL1 is substituted with S84A.
- SEQ ID NO: 12 represents the HIV TAT transduction domain sequence as a control sequence.
- the gastric cancer cell line NUGC3 was cultured in a 6-well plate the next day and cultured in serum-free cell culture for 24 hours.
- TGF- ⁇ and a control peptide fragment (SEQ ID NO: 12), a peptide fragment containing serine 84 of VGLL1 (SEQ ID NO: 27), and a mutant peptide fragment containing alanine 84 of VGLL1 (SEQ ID NO: 28) were treated for 18 hours .
- Proteins were extracted from the cells using a Lipa buffer and separated by electrophoresis, and then protein expression of genes was confirmed by using an antibody in the moved polyvinylidene fluoride membrane.
- FIG. 8 The results are shown in FIG. 8 .
- the increased expression of MMP9 in TGF- ⁇ was reduced by treatment with a peptide fragment containing serine 84 of VGLL1.
- the sequence of the mutant peptide fragment including alanine 84 of VGLL1 was not affected by the treatment of the peptide fragment. From these results, it was confirmed that the peptide fragment sequence containing serine 84 of VGLL1 according to the present invention can exhibit an excellent effect in the treatment of cancer.
- Example 6-2 Confirmation of cancer cell proliferation inhibitory effect by S84 VGLL1 peptide fragment
- the gastric cancer cell line NUGC3 was cultured in a 96-well plate the next day, and the peptide fragment was treated, and cell proliferation was analyzed using a real-time cell analysis system (product name: Incucyte).
- FIG. 9 The results are shown in FIG. 9 .
- the S84 VGLL1 peptide fragment exhibited an effect of inhibiting cancer cell proliferation.
- the control peptide fragment or the mutated VGLL1 peptide fragment containing an alanine at position 84 in which the position of S84 is mutated did not have any effect on the inhibition of cancer cell proliferation.
- the gastric cancer cell invasion experiment by the VGLL1 peptide fragment was performed in a similar manner to Example 1-2.
- the gastric cancer cell line NUGC3 was placed in an insert together with the peptide fragment, and after 48 hours of cell culture, the insert was fixed in 10% formalin solution, and the cells that migrated downward were stained with 0.4% Sulforhodamine B solution to confirm.
- FIG. 10 The results are shown in FIG. 10 .
- the VGLL1 peptide fragment sequence including S84 exhibited an effect of inhibiting cancer cell invasion, whereas the sequence in which the corresponding position was mutated did not exhibit such an effect.
- the gastric cancer cell line NUGC3 was cultured in a 96-well plate and treated with 60 ⁇ M peptide the next day, and cell proliferation was analyzed using a real-time cell analysis system (product name: Incucyte).
- FIG. 11 A is a real-time cell proliferation graph
- FIG. B is a graph drawn based on 100% control peptide after 4 days of cell proliferation.
- the peptide fragment sequence containing the S84 serine of VGLL1 according to the present invention exhibits an excellent effect in the treatment of cancer through inhibition of proliferation and invasion of cancer cells.
- the VGLL1 S84 peptide sequence of SEQ ID NO: 27 was treated in various cancer cell lines.
- the cancer cells of Table 8 were cultured in a 96-well plate and treated with 60 ⁇ M peptide the next day, and cell proliferation was analyzed using a real-time cell analysis system (product name: Incucyte).
- the S84 VGLL1 peptide fragment exhibits an excellent effect in inhibiting the proliferation of gastric cancer cells as well as colon cancer, lung cancer, liver cancer, prostate cancer, breast cancer, cervical cancer and ovarian cancer cells. Confirmed.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
Description
서열번호2 | 서열 77-91 | PNQWRYSSPWTKPQP |
서열번호3 | 서열 78-90 | NQWRYSSPWTKPQ |
서열번호4 | 서열 79-89 | QWRYSSPWTKP |
서열번호5 | 서열 80-88 | WRYSSPWTK |
서열번호6 | 서열 80-87 | WRYSSPWT |
서열번호7 | 서열 80-86 | WRYSSPW |
서열번호8 | 서열 81-87 | RYSSPWT |
서열번호9 | 서열 82-88 | YSSPWTK |
서열번호 10 | P85A | PNQWR YSSAWTKPQP |
서열번호 11 | T87A | PNQWRY SSPWAKPQP |
HIV-1 Tat(서열번호 12) | YGRKKRRQRRR |
Penetratin(서열번호 13) | RQIKIWFQNRRMKWKK |
HSV VP22(서열번호 14) | DAATATRGRSAASRPTERPRAPARSASRPRRPVE |
MTS(서열번호 15) | AAVALLPAVLLAAP |
Transportan(서열번호 16) | GWTLNSAGYLLGKINLKALAALAKKIL |
PEP-1(서열번호 17) | KETWWETWWTEWSQPKKKRKV |
Poly arginine(서열번호 18) | RRRRRRR |
PTD-5(서열번호 19) | RRQRRTSKLMKR |
프라이머 | 서열 |
MMP9-F | 5'-TCTATGGTCCTCGCCCTGAA-3'(서열번호 20) |
MMP9-R | 5'-CATCGTCCACCGGACTCAAA-3'(서열번호 21) |
서열 | |
siMMP9 | 5'-CCACAACAUCACCUAUUGGAUdTdT-3' |
펜타이드 단편 | 서열 |
VGLL1 (S84) | YGRKKRRQRRRPNQWRYSSPWTKPQP (서열번호 27) |
VGLL1 (S84A) | YGRKKRRQRRRPNQWRYSAPWTKPQP (서열번호 28) |
Control peptide | YGRKKRRQRRR (서열번호 12) |
펩타이드 | 서열 |
Control | YGRKKRRQRRR (서열번호 12) |
VGLL1 S84-S | YGRKKRRQRRR- YSSPWTK (서열번호 29) |
VGLL1 S84 | YGRKKRRQRRR-PNQWR YSSPWTKPQP (서열번호 27) |
VGLL1 S84A | YGRKKRRQRRR-PNQWR YSAPWTKPQP (서열번호 28) |
VGLL1 P85A | YGRKKRRQRRR-PNQWR YSSAWTKPQP (서열번호 30) |
VGLL1 T87A | YGRKKRRQRRR-PNQWR YSSPWAKPQP (서열번호 31) |
암 종류 | 암 세포주 명 |
위암 | NUGC3 |
AG5 | |
NCI-N87 | |
SNU484 | |
MKN1 | |
대장암 | SW620 |
HCT116 | |
WiDr | |
폐암 | A549 |
H1650 | |
H1299 | |
간암 | HepG2 |
SNU354 | |
췌장암 | ASPC1 |
PANC1 | |
Mia-paca2 | |
유방암 | MCF7 |
SKBR3 | |
자궁경부암 | Hela |
난소암 | SK-OV3 |
Claims (11)
- 서열번호 1의 VGLL1의 펩타이드 서열의 84번째 세린(Serine)을 포함하고, 35개 이하의 아미노산 길이를 가지는 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항에 있어서, 상기 VGLL1 펩타이드 단편 또는 이의 변이체는 6 내지 25개의 아미노산 서열을 가지는 것인 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항에 있어서, 상기 VGLL1 펩타이드 단편 또는 이의 변이체는 서열번호 1의 52번 내지 115번째 사이의 아미노산 서열에서 84번째 세린 서열을 포함하는 것인 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항에 있어서, 상기 VGLL1 펩타이드 단편 또는 이의 변이체는 84번째 세린 및 이에 인접한 6개 내지 20개 아미노산으로 이루어진 것인 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항에 있어서, 상기 VGLL1 펩타이드 단편 또는 이의 변이체는 서열번호 2 내지 9로 이루어진 군으로부터 선택되는 어느 하나인 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항에 있어서, 세포 투과성 펩타이드를 더 포함하는 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제6항에 있어서, 상기 세포 투과성 펩타이드는 서열번호 12 내지 19로 이루어진 군으로부터 선택되는 어느 하나인 VGLL1 펩타이드 단편 또는 이의 변이체.
- 제1항 내지 제7항 중 어느 한 항에 따른 VGLL1 펩타이드 단편 또는 이의 변이체를 포함하는 암의 예방 또는 치료용 약제학적 조성물.
- 제8항에 있어서, 상기 암은 위암, 간암, 대장암, 폐암, 유방암, 췌장암, 두경부 편평암 세포 암종, 식도암, 난소암, 자궁경부암, 자궁내막암, 중피종, 흑색종, 육종, 골육종, 지방육종, 갑상선암, 유건종 및 혈액암으로 이루어진 군으로부터 선택되는 어느 하나인 암의 예방 또는 치료용 약제학적 조성물.
- 제9항에 있어서, 상기 암은 위암인 암의 예방 또는 치료용 약제학적 조성물.
- 제1항의 조성물을 대상체에 투여하는 단계를 포함하는 암의 치료 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180023076.4A CN115298203A (zh) | 2020-03-27 | 2021-03-22 | 包含vgll1肽的用于治疗癌症的组合物 |
JP2022558391A JP7531931B2 (ja) | 2020-03-27 | 2021-03-22 | Vgll1ペプチドを含む癌治療用組成物 |
AU2021244056A AU2021244056B2 (en) | 2020-03-27 | 2021-03-22 | Composition comprising VGLL1 peptide for treatment of cancer |
BR112022019454A BR112022019454A2 (pt) | 2020-03-27 | 2021-03-22 | Composição compreendendo peptídeo vgll1 para tratamento de câncer |
EP21775333.4A EP4130025A4 (en) | 2020-03-27 | 2021-03-22 | COMPOSITION CONTAINING VGLL1 PEPTIDE FOR THE TREATMENT OF CANCER |
AU2024201112A AU2024201112A1 (en) | 2020-03-27 | 2024-02-21 | Composition comprising VGLL1 peptide for treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0037335 | 2020-03-27 | ||
KR20200037335 | 2020-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021194186A1 true WO2021194186A1 (ko) | 2021-09-30 |
Family
ID=77892463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/003496 WO2021194186A1 (ko) | 2020-03-27 | 2021-03-22 | Vgll1 펩타이드를 포함하는 암 치료용 조성물 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4130025A4 (ko) |
JP (1) | JP7531931B2 (ko) |
KR (2) | KR20210120882A (ko) |
CN (1) | CN115298203A (ko) |
AU (2) | AU2021244056B2 (ko) |
BR (1) | BR112022019454A2 (ko) |
WO (1) | WO2021194186A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022220632A1 (ko) * | 2021-04-15 | 2022-10-20 | 원큐어젠 주식회사 | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527895B2 (en) * | 2009-10-07 | 2016-12-27 | Robert J. Hickey | CAPCNA peptide therapeutics for cancer |
KR101714649B1 (ko) * | 2013-10-30 | 2017-03-10 | 한국생명공학연구원 | 암 치료 또는 암 전이 타겟으로서 vgll1의 용도 |
KR20190057130A (ko) * | 2016-10-07 | 2019-05-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Hla-제한 vgll1 펩타이드 및 그의 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055320A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CA2343602A1 (en) * | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
AU2020264492A1 (en) * | 2019-04-30 | 2021-10-14 | Gigagen, Inc. | Recombinant polyclonal proteins and methods of use thereof |
KR20220142954A (ko) * | 2021-04-15 | 2022-10-24 | 한국생명공학연구원 | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
-
2021
- 2021-03-22 WO PCT/KR2021/003496 patent/WO2021194186A1/ko active Application Filing
- 2021-03-22 AU AU2021244056A patent/AU2021244056B2/en active Active
- 2021-03-22 JP JP2022558391A patent/JP7531931B2/ja active Active
- 2021-03-22 EP EP21775333.4A patent/EP4130025A4/en active Pending
- 2021-03-22 CN CN202180023076.4A patent/CN115298203A/zh active Pending
- 2021-03-22 BR BR112022019454A patent/BR112022019454A2/pt not_active Application Discontinuation
- 2021-03-24 KR KR1020210038340A patent/KR20210120882A/ko active Application Filing
-
2024
- 2024-02-21 AU AU2024201112A patent/AU2024201112A1/en active Pending
- 2024-08-05 KR KR1020240104064A patent/KR20240124255A/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527895B2 (en) * | 2009-10-07 | 2016-12-27 | Robert J. Hickey | CAPCNA peptide therapeutics for cancer |
KR101714649B1 (ko) * | 2013-10-30 | 2017-03-10 | 한국생명공학연구원 | 암 치료 또는 암 전이 타겟으로서 vgll1의 용도 |
KR20190057130A (ko) * | 2016-10-07 | 2019-05-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Hla-제한 vgll1 펩타이드 및 그의 용도 |
Non-Patent Citations (5)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005, LIPPENCOTT WILLIAMS & WILKINS |
IM JOO-YOUNG; KIM DA-MI; PARK HYUNKYUNG; KANG MI-JUNG; KIM DA-YOON; CHANG KWAN YOUNG; KIM BO-KYUNG; WON MISUN: "VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, vol. 1868, no. 1, 16 October 2020 (2020-10-16), NL, XP086349123, ISSN: 0167-4889, DOI: 10.1016/j.bbamcr.2020.118892 * |
JIAO SHI; WANG HUIZHEN; SHI ZHUBING; DONG AIMEI; ZHANG WENJING; SONG XIAOMIN; HE FENG; WANG YICUI; ZHANG ZHENZHEN; WANG WENJIA; WA: "A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer", CANCER CELL, CELL PRESS, US, vol. 25, no. 2, 10 February 2014 (2014-02-10), US, pages 166 - 180, XP028610274, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2014.01.010 * |
KIM BO-KYUNG, CHEONG JAE-HO, IM JOO-YOUNG, BAN HYUN SEUNG, KIM SEON-KYU, KANG MI-JUNG, LEE JUNGWOON, KIM SEON-YOUNG, PARK KYUNG-CH: "PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer", CANCERS, vol. 11, no. 12, 3 December 2019 (2019-12-03), pages 1923, XP055852725, DOI: 10.3390/cancers11121923 * |
See also references of EP4130025A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022220632A1 (ko) * | 2021-04-15 | 2022-10-20 | 원큐어젠 주식회사 | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2023520864A (ja) | 2023-05-22 |
AU2021244056A1 (en) | 2022-10-06 |
EP4130025A4 (en) | 2024-05-29 |
BR112022019454A2 (pt) | 2022-12-13 |
CN115298203A (zh) | 2022-11-04 |
KR20210120882A (ko) | 2021-10-07 |
JP7531931B2 (ja) | 2024-08-13 |
AU2021244056B2 (en) | 2024-04-04 |
KR20240124255A (ko) | 2024-08-16 |
EP4130025A1 (en) | 2023-02-08 |
AU2024201112A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015156649A1 (ko) | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2015076621A1 (ko) | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
CA2387184C (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
WO2013169077A1 (ko) | 악액질 예방 또는 치료용 조성물 | |
WO2014046490A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2014046478A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2015005723A1 (ko) | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 | |
WO2014183491A1 (zh) | 具有抗肿瘤活性的多肽及其用途 | |
JP2010526527A (ja) | 抗腫瘍活性を有する新規なポリペプチド | |
KR20240124255A (ko) | Vgll1 펩타이드를 포함하는 암 치료용 조성물 | |
WO2021096275A1 (ko) | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 | |
WO2022220632A1 (ko) | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
WO2022215946A1 (ko) | 세포 투과성 펩타이드 변이체 및 이의 용도 | |
WO2022005174A1 (ko) | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 | |
WO2023249408A1 (ko) | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 | |
US11214774B2 (en) | PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment | |
WO2022245183A1 (en) | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant | |
KR20140138507A (ko) | 아넥신 A1 결합단백질, p53 단백질, 및 p18 또는 p16 단백질을 포함하는 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 조성물 | |
WO2016099091A1 (ko) | 페길화된 vegf 트랩 및 이의 제조방법 | |
WO2022108309A1 (ko) | 인산화된 비멘틴의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법 | |
WO2016159695A1 (ko) | Ssu72를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 | |
KR102365266B1 (ko) | 미나리 유래 폴리펩티드 및 상기 폴리펩티드를 포함하는 약학적 조성물 | |
WO2021080400A1 (ko) | 미나리 유래 폴리펩티드 및 상기 폴리펩티드를 포함하는 약학적 조성물 | |
WO2015065020A1 (ko) | C형 간염 바이러스 감염 질환의 예방 또는 치료용 약학 조성물 | |
WO2021025352A1 (ko) | Fgf2 또는 api5 유래 펩타이드를 발현하는 항암 바이러스 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21775333 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217054293 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2022558391 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019454 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021244056 Country of ref document: AU Date of ref document: 20210322 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021775333 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2021775333 Country of ref document: EP Effective date: 20221027 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022019454 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220927 |